Eagle Pharmaceuticals Inc. (EGRX): Douglas Braunstein of Hudson Executive Capital Appointed Chairman

Page 5 of 7 – SEC Filing
CUSIP No.  269796108
SCHEDULE 13D
Page 5 of 6 Pages
ITEM 1. SECURITY AND ISSUER
This first amendment to Schedule 13D (“Amendment No. 1”) relates to the Common Stock, par value $0.001 per share (the “Shares”), of Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and supplements the information set forth in Schedule 13D filed on June 27, 2016 (the “Original Schedule 13D” and together with this Amendment No. 1, the “Schedule 13D”). This Amendment No. 1 is being filed to report, among other things, that pursuant to an agreement with the Company described herein, Mr. Braunstein has joined the Board of the Company.  Item 4, Item 6 and Item 7 of Schedule 13D have been amended as follows:
ITEM 4. PURPOSE OF TRANSACTION
On July 5, 2016, Mr. Braunstein became a director of the Company.
The Reporting Persons intend to review their respective investment in the Company on a continuing basis.  Depending on various factors, including, without limitation, the outcome of any discussions referenced above, the Company’s financial position and strategic direction, actions taken by the Board, price levels of the Shares, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, the Reporting Persons may from time to time and at any time in the future take such actions with respect to the investment in the Company as they deem appropriate, including: (i) acquiring additional Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of the Shares or the Company (collectively, “Securities”) of the Company in the open market or otherwise; (ii) disposing of any or all of their Securities in the open market or otherwise; (iii) engaging in any hedging or similar transactions with respect to the Securities; or (iv) proposing or considering one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D.  In connection with his position as a director of the Company, Mr. Braunstein may evaluate or consider matters set forth in subsections (a) through (j) of Item 4 of Schedule 13D.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
On July 5, 2016, Mr. Braunstein accepted an invitation from the Company to become a director of the Board.  In addition, Mr. Braunstein will serve as a member of the compensation committee of the Board.

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)